Allarity Therapeutics Inc. has filed a prospectus supplement on April 9, 2024, to increase the maximum aggregate offering price of its common stock from $947,000 to $1,350,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company's public float was valued at approximately $4,052,088, with a closing stock price of $0.43 on February 9, 2024. Allarity Therapeutics has already sold $654,871 worth of common stock in the past 12 months and can sell up to an additional $695,825 under the current SEC guidelines. The company is restricted to selling no more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, as long as the public float remains below $75 million.

Allarity Therapeutics Inc. has filed a prospectus supplement on April 9, 2024, to increase the maximum aggregate offering price of its common stock from $947,000 to $1,350,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company's public float was valued at approximately $4,052,088, with a closing stock price of $0.43 on February 9, 2024. Allarity Therapeutics has already sold $654,871 worth of common stock in the past 12 months and can sell up to an additional $695,825 under the current SEC guidelines. The company is restricted to selling no more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, as long as the public float remains below $75 million.